Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
Anderson
D R
DR
IDEC Pharmaceuticals Corporation, San Diego, CA 92121, USA.
Grillo-López
A
A
Varns
C
C
Chambers
K S
KS
Hanna
N
N
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000920:Antibody-Dependent Cell Cytotoxicity; D015703:Antigens, CD / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D017322:Clinical Trials, Phase II as Topic; D003167:Complement Activation; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D018951:Antigens, CD20; D000069283:Rituximab